Pieris Retained Earnings vs Net Receivables Analysis

PIRS Stock

USD 15.93 0.08 0.50%

Pieris Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pieris Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pieris Pharmaceuticals is a good investment. Please check the relationship between Pieris Pharmaceuticals Retained Earnings and its Net Receivables accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Retained Earnings vs Net Receivables

Retained Earnings vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pieris Pharmaceuticals Retained Earnings account and Net Receivables. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Pieris Pharmaceuticals' Retained Earnings and Net Receivables is -0.11. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Pieris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pieris Pharmaceuticals' Retained Earnings and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Pieris Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Retained Earnings i.e., Pieris Pharmaceuticals' Retained Earnings and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.11

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Net Receivables

Most indicators from Pieris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.Issuance Of Capital Stock is likely to gain to about 22.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.

	2021	2022	2023	2024 (projected)
Net Interest Income	4K	721K	1.7M	936.8K
Interest Income	4K	721K	1.7M	1.8M

Net Interest Income Interest Income

Pieris Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab
Total Assets		0.7	0.4	0.9	0.8	0.52	-0.89	-0.49	0.77	0.92	0.68	0.74	0.49	0.98	0.55	0.7	0.55	0.91	0.18	0.45	0.66	0.97	0.97	0.06	0.33	0.9
Short Long Term Debt Total	0.7		0.04	0.53	0.76	0.49	-0.63	-0.56	0.5	0.63	0.59	0.77	0.5	0.68	0.39	0.86	0.73	0.7	0.2	0.5	0.68	0.59	0.71	0.55	0.31	0.67
Other Current Liab	0.4	0.04		0.5	0.32	0.48	-0.48	-0.52	0.44	0.49	0.44	0.14	0.36	0.38	-0.1	0.41	0.22	0.35	0.57	0.59	0.54	0.38	0.39	-0.48	0.74	0.28
Total Current Liabilities	0.9	0.53	0.5		0.54	0.35	-0.8	-0.43	0.6	0.79	0.53	0.47	0.28	0.89	0.67	0.6	0.44	0.8	0.25	0.39	0.56	0.95	0.88	0.04	0.38	0.84
Total Stockholder Equity	0.8	0.76	0.32	0.54		0.64	-0.8	-0.62	0.82	0.82	0.64	0.85	0.56	0.81	0.13	0.78	0.68	0.73	0.33	0.65	0.74	0.63	0.83	0.16	0.39	0.67
Property Plant And Equipment Net	0.52	0.49	0.48	0.35	0.64		-0.41	-0.91	0.65	0.49	0.92	0.78	0.91	0.43	0.08	0.74	0.72	0.71	0.72	0.86	0.87	0.42	0.54	-0.24	0.66	0.55
Net Debt	-0.89	-0.63	-0.48	-0.8	-0.8	-0.41		0.4	-0.66	-0.98	-0.52	-0.66	-0.4	-0.92	-0.28	-0.62	-0.46	-0.74	-0.17	-0.49	-0.56	-0.83	-0.88	-0.13	-0.29	-0.74
Retained Earnings	-0.49	-0.56	-0.52	-0.43	-0.62	-0.91	0.4		-0.56	-0.43	-0.82	-0.7	-0.76	-0.42	-0.11	-0.85	-0.86	-0.65	-0.88	-0.95	-0.94	-0.39	-0.55	0.09	-0.76	-0.54
Accounts Payable	0.77	0.5	0.44	0.6	0.82	0.65	-0.66	-0.56		0.71	0.69	0.69	0.43	0.74	0.34	0.64	0.52	0.74	0.41	0.56	0.67	0.67	0.77	-0.07	0.44	0.66
Cash	0.92	0.63	0.49	0.79	0.82	0.49	-0.98	-0.43	0.71		0.62	0.73	0.5	0.92	0.29	0.64	0.48	0.77	0.18	0.51	0.61	0.85	0.87	0.06	0.3	0.74
Non Current Assets Total	0.68	0.59	0.44	0.53	0.64	0.92	-0.52	-0.82	0.69	0.62		0.81	0.87	0.58	0.34	0.81	0.74	0.82	0.56	0.74	0.88	0.63	0.63	-0.13	0.66	0.67
Non Currrent Assets Other	0.74	0.77	0.14	0.47	0.85	0.78	-0.66	-0.7	0.69	0.73	0.81		0.76	0.69	0.21	0.8	0.83	0.8	0.39	0.68	0.8	0.62	0.73	0.11	0.29	0.68
Other Assets	0.49	0.5	0.36	0.28	0.56	0.91	-0.4	-0.76	0.43	0.5	0.87	0.76		0.41	0.01	0.64	0.61	0.67	0.46	0.71	0.74	0.42	0.47	-0.21	0.52	0.52
Cash And Short Term Investments	0.98	0.68	0.38	0.89	0.81	0.43	-0.92	-0.42	0.74	0.92	0.58	0.69	0.41		0.48	0.66	0.5	0.88	0.12	0.4	0.59	0.95	0.97	0.07	0.29	0.89
Net Receivables	0.55	0.39	-0.1	0.67	0.13	0.08	-0.28	-0.11	0.34	0.29	0.34	0.21	0.01	0.48		0.3	0.18	0.54	-0.04	-0.05	0.19	0.66	0.51	0.35	0.06	0.61
Common Stock Total Equity	0.7	0.86	0.41	0.6	0.78	0.74	-0.62	-0.85	0.64	0.64	0.81	0.8	0.64	0.66	0.3		0.91	0.75	0.6	0.8	0.95	0.6	0.71	0.21	0.68	0.66
Common Stock Shares Outstanding	0.55	0.73	0.22	0.44	0.68	0.72	-0.46	-0.86	0.52	0.48	0.74	0.83	0.61	0.5	0.18	0.91		0.66	0.68	0.79	0.91	0.43	0.58	0.12	0.53	0.55
Non Current Liabilities Total	0.91	0.7	0.35	0.8	0.73	0.71	-0.74	-0.65	0.74	0.77	0.82	0.8	0.67	0.88	0.54	0.75	0.66		0.33	0.58	0.74	0.89	0.92	-0.05	0.45	0.97
Inventory	0.18	0.2	0.57	0.25	0.33	0.72	-0.17	-0.88	0.41	0.18	0.56	0.39	0.46	0.12	-0.04	0.6	0.68	0.33		0.89	0.74	0.1	0.28	-0.21	0.7	0.23
Other Current Assets	0.45	0.5	0.59	0.39	0.65	0.86	-0.49	-0.95	0.56	0.51	0.74	0.68	0.71	0.4	-0.05	0.8	0.79	0.58	0.89		0.88	0.33	0.53	-0.09	0.72	0.47
Other Stockholder Equity	0.66	0.68	0.54	0.56	0.74	0.87	-0.56	-0.94	0.67	0.61	0.88	0.8	0.74	0.59	0.19	0.95	0.91	0.74	0.74	0.88		0.55	0.66	-0.04	0.77	0.61
Total Liab	0.97	0.59	0.38	0.95	0.63	0.42	-0.83	-0.39	0.67	0.85	0.63	0.62	0.42	0.95	0.66	0.6	0.43	0.89	0.1	0.33	0.55		0.92	0.01	0.27	0.9
Total Current Assets	0.97	0.71	0.39	0.88	0.83	0.54	-0.88	-0.55	0.77	0.87	0.63	0.73	0.47	0.97	0.51	0.71	0.58	0.92	0.28	0.53	0.66	0.92		0.08	0.35	0.94
Short Term Debt	0.06	0.55	-0.48	0.04	0.16	-0.24	-0.13	0.09	-0.07	0.06	-0.13	0.11	-0.21	0.07	0.35	0.21	0.12	-0.05	-0.21	-0.09	-0.04	0.01	0.08		-0.2	0.03
Common Stock	0.33	0.31	0.74	0.38	0.39	0.66	-0.29	-0.76	0.44	0.3	0.66	0.29	0.52	0.29	0.06	0.68	0.53	0.45	0.7	0.72	0.77	0.27	0.35	-0.2		0.36
Other Liab	0.9	0.67	0.28	0.84	0.67	0.55	-0.74	-0.54	0.66	0.74	0.67	0.68	0.52	0.89	0.61	0.66	0.55	0.97	0.23	0.47	0.61	0.9	0.94	0.03	0.36

Click cells to compare fundamentals

Pieris Pharmaceuticals Account Relationship Matchups

Pieris Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Other Current Liab	5.0M	6.6M	15.8M	10.7M	8.6M	6.6M
Total Current Liabilities	27.0M	22.1M	50.6M	36.6M	11.9M	11.3M
Total Stockholder Equity	51.4M	31.0M	50.8M	27.9M	26.8M	28.8M
Property Plant And Equipment Net	22.9M	26.0M	23.0M	20.7M	23.8M	25.0M
Net Debt	(46.0M)	(53.5M)	(103.9M)	(25.5M)	(17.4M)	(18.3M)
Retained Earnings	(174.2M)	(211.4M)	(257.1M)	(290.4M)	(315.0M)	(299.2M)
Accounts Payable	10.1M	1.8M	8.6M	4.2M	3.4M	3.6M
Cash	62.3M	70.4M	117.8M	38.6M	17.4M	16.5M
Non Current Assets Total	26.1M	29.3M	25.9M	22.1M	25.4M	13.5M
Non Currrent Assets Other	3.1M	3.3M	2.9M	1.4M	1.6M	1.1M
Other Assets	910K	3.1M	7.2M	2.9M	3.3M	3.5M
Cash And Short Term Investments	104.2M	70.4M	117.8M	59.2M	26.4M	25.0M
Net Receivables	6.8M	1.7M	3.3M	5.8M	572K	543.4K
Common Stock Total Equity	54K	55K	56K	72K	82.8K	42.7K
Common Stock Shares Outstanding	632.8K	681.0K	806.8K	927.2K	1.1M	674.0K
Liabilities And Stockholders Equity	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Non Current Liabilities Total	62.7M	51.8M	52.2M	31.0M	35.6M	30.4M
Other Current Assets	4.1M	7.2M	13.1M	8.4M	11.7M	12.3M
Other Stockholder Equity	227.5M	242.7M	307.0M	318.5M	341.6M	201.9M
Total Liab	89.7M	74.0M	102.8M	67.6M	11.9M	11.3M
Total Current Assets	115.0M	75.7M	127.6M	73.4M	38.7M	69.0M
Common Stock	55K	56K	72K	74K	98K	57.9K
Other Liab	47.3M	35.9M	38.4M	18.7M	21.5M	26.7M
Net Tangible Assets	51.4M	31.0M	50.8M	27.9M	32.1M	31.6M
Current Deferred Revenue	11.3M	12.6M	25.1M	20.8M	23.9M	17.9M
Retained Earnings Total Equity	(147.1M)	(174.2M)	(211.4M)	(257.1M)	(231.4M)	(219.9M)
Short Term Investments	34.8M	53.2M	41.9M	20.5M	9.0M	15.9M
Capital Surpluse	189.9M	227.5M	242.7M	307.0M	353.0M	370.7M
Property Plant And Equipment Gross	22.9M	22.0M	23.0M	20.7M	23.8M	25.0M
Accumulated Other Comprehensive Income	(2.0M)	(295K)	829K	(254K)	28K	29.4K
Non Current Liabilities Other	27K	62.7M	6K	52.2M	60.1M	63.1M
Property Plant Equipment	19.5M	26.0M	23.0M	20.7M	23.8M	25.0M
Net Invested Capital	51.4M	31.0M	50.8M	27.9M	32.1M	39.0M
Net Working Capital	88.0M	53.6M	77.1M	36.8M	33.2M	51.6M
Capital Stock	55K	56K	72K	74K	85.1K	68.4K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC